Enlivex Therapeutics Ltd. (FRA:1BT)

Germany flag Germany · Delayed Price · Currency is EUR
0.8250
+0.0250 (3.12%)
At close: Nov 28, 2025
-19.90%
Market Cap19.02M
Revenue (ttm)n/a
Net Income (ttm)-10.83M
Shares Outn/a
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,000
Average Volume375
Open0.7650
Previous Close0.8000
Day's Range0.7650 - 0.8250
52-Week Range0.7500 - 1.7100
Betan/a
RSI45.80
Earnings DateNov 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Country Israel
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1BT
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.